Stay updated with breaking news from Presection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ben Levy, MD, reviews the 5-year update and clinical implications of the PACIFIC study which evaluated consolidation immunotherapy in unresectable early-stage NSCLC.
A panel of experts offers their insights into which patients with resectable early-stage NSCLC might be suitable for neoadjuvant versus adjuvant chemoimmunotherapy.
David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC
This_ it and make sure it works for us. this issue — it and make sure it works for us. this issue of— it and make sure it works for us. this issue of regulation, it's not easy, is it? this issue of regulation, it's not easy. is it?— this issue of regulation, it's not easy, is it? it's not easy because nobody knows — easy, is it? it's not easy because nobody knows how— easy, is it? it's not easy because nobody knows how the _ easy, is it? it's not easy because i nobody knows how the technology's going _ nobody knows how the technology's going to _ nobody knows how the technology's goi...
Although patients with metastatic nonseminomatous germ-cell tumors who had teratoma in the primary tumor were found to have a higher rate of teratoma in residual non-retroperitoneal disease following chemotherapy, those without teratoma in the primary tumor could have teratoma or active testicular germ-cell tumors in residual disease post-chemotherapy and should be considered for resection.